|
22 Companies |
|
13 Products |
|
13 Products |
|
29 Mechanisms of Action |
|
3 Trials |
|
142 News |
|
| «123 |
- | Trial completion: Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=36, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed
- Enrollment change: Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer (clinicaltrials.gov) - Dec 11, 2012
P=N/A, N=1, Terminated, Sponsor: Stanford University
Recruiting --> Completed N=34 --> 1
- New P3 trial: A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing (clinicaltrials.gov) - Dec 11, 2012
P3, N=1, Terminated, Sponsor: Shire Regenerative Medicine, Inc.
- lovastatin / Generic mfg.
Trial withdrawal: Novel Treatment for Syndromic Ichthyoses (clinicaltrials.gov) - Nov 28, 2012
P2, N=0, Withdrawn, Sponsor: Northwestern University
N=34 --> 1 Not yet recruiting --> Withdrawn
- lovastatin / Generic mfg.
Enrollment change: Novel Treatment for Syndromic Ichthyoses (clinicaltrials.gov) - Nov 28, 2012
P2, N=0, Withdrawn, Sponsor: Northwestern University
Not yet recruiting --> Withdrawn N=15 --> 0
- Enrollment change: Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=35, Completed, Sponsor: Northwestern University
N=15 --> 0 N=100 --> 35
- | Trial completion: Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=35, Completed, Sponsor: Northwestern University
N=100 --> 35 Active, not recruiting --> Completed
- Trial completion: Study of Alwextin® Cream in Treating Epidermolysis Bullosa (clinicaltrials.gov) - Nov 28, 2012
P2, N=8, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Increlex (mecasermin) / Ipsen
Trial completion: IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients (clinicaltrials.gov) - Nov 18, 2012
P=N/A, N=15, Completed, Sponsor: Bispebjerg Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Ca-Art-PXE: Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE) (clinicaltrials.gov) - Nov 13, 2012
P=N/A, N=71, Completed, Sponsor: University Hospital, Angers
Active, not recruiting --> Completed Recruiting --> Completed
- Trial termination: Personalized Interactive Laser Therapy of Port Wine Stain (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=6, Terminated, Sponsor: University of Arkansas
Recruiting --> Completed Recruiting --> Terminated; PI moved out of state.
- Enrollment change: Personalized Interactive Laser Therapy of Port Wine Stain (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=6, Terminated, Sponsor: University of Arkansas
Recruiting --> Terminated; PI moved out of state. N=15 --> 6
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (clinicaltrials.gov) - Oct 23, 2012
P1/2, N=18, Completed, Sponsor: Manhattan Eye, Ear & Throat Hospital
N=15 --> 6 N=40 --> 18
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: FVF4140S: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (clinicaltrials.gov) - Oct 23, 2012
P1/2, N=18, Completed, Sponsor: Manhattan Eye, Ear & Throat Hospital
N=40 --> 18 Recruiting --> Completed
- Increlex (mecasermin) / Ipsen
Enrollment change: IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients (clinicaltrials.gov) - Oct 8, 2012
P=N/A, N=15, Completed, Sponsor: Bispebjerg Hospital
Recruiting --> Completed N=20 --> 15
- Enrollment closed: EVACARNEY: Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the CARNEY Complex (CNC) (clinicaltrials.gov) - Jul 24, 2012
P=N/A, N=133, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=20 --> 15 Recruiting --> Active, not recruiting
- || Enrollment closed: Vascular Fundus Changes in Patients With High Probability of Chronic Cerebrospinal Venous Insufficiency (CCSVI) (clinicaltrials.gov) - Jul 13, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: Genetic Disease Investigators
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Filsuvez (AP101) / Amryt
Trial completion: Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10) (clinicaltrials.gov) - Jul 9, 2012
P2, N=10, Completed, Sponsor: Birken AG
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Edsivo (celiprolol) / Acer Therap
Enrollment change: Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type (clinicaltrials.gov) - Jul 3, 2012
P4, N=54, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Completed N=100 --> 54
- Review, Enrollment change: Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=11, Completed, Sponsor: Edimer Pharmaceuticals
N=100 --> 54 N=50 --> 11
- Enrollment change: Sweat Duct Imaging in Mother/Newborn Dyads (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=28, Completed, Sponsor: Edimer Pharmaceuticals
N=50 --> 11 N=40 --> 28
- Enrollment change: Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=27, Completed, Sponsor: Edimer Pharmaceuticals
N=40 --> 28 N=40 --> 27
- Clinical: Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012) (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=30, Completed, Sponsor: Edimer Pharmaceuticals
- ||| Trial completion: Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=64, Completed, Sponsor: Edimer Pharmaceuticals
N=40 --> 27 Recruiting --> Completed
- | Trial completion: Sweat Duct Imaging in Mother/Newborn Dyads (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=28, Completed, Sponsor: Edimer Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=27, Completed, Sponsor: Edimer Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa (clinicaltrials.gov) - Jun 12, 2012
P4, N=18, Recruiting, Sponsor: University Hospital, Basel, Switzerland
- Trial withdrawal: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - May 14, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
Not yet recruiting --> Withdrawn N=10 --> 0
- ||| Altabax (retapamulin) / GSK, Almirall
Enrollment change: Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. (clinicaltrials.gov) - Apr 11, 2012
P4, N=60, Completed, Sponsor: GlaxoSmithKline
N=10 --> 0 N=87 --> 60
- Amevive (alefacept) / Astellas
Trial suspension: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Apr 3, 2012
P=N/A, N=5, Suspended, Sponsor: Emory University
N=87 --> 60 Recruiting --> Suspended
- recombinant ectodysplasin A1 (APO200) / Onxeo, Pierre Fabre
New P1 trial: A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200 (clinicaltrials.gov) - Mar 25, 2012
P1, N=6, Completed, Sponsor: Edimer Pharmaceuticals
- linsitinib (ASP7487) / VasaraGen
New P2 trial, Stroma: Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Mar 20, 2012
P2, N=40, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Trial completion: MSSkin: Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=60, Completed, Sponsor: University of North Carolina, Charlotte
Recruiting --> Suspended Enrolling by invitation --> Completed
- | Trial completion, Review: Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=11, Completed, Sponsor: Edimer Pharmaceuticals
Enrolling by invitation --> Completed Recruiting --> Completed
- New P2 trial: A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa (clinicaltrials.gov) - Feb 6, 2012
P2, N=0, Withdrawn, Sponsor: Healthpoint
- Trial termination: Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=7, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Completed Recruiting --> Terminated; Competing studies
- Enrollment change: Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=7, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Terminated; Competing studies N=30 --> 7
- New P4 trial: The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) (clinicaltrials.gov) - Feb 5, 2012
P4, N=6, Completed, Sponsor: Maastricht University Medical Center
- timbetasin topical (RGN-137) / RegeneRx
Trial termination: A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa (clinicaltrials.gov) - Jan 25, 2012
P2, N=30, Terminated, Sponsor: RegeneRx Biopharmaceuticals, Inc.
N=30 --> 7 Completed --> Terminated; Lack of patient availability and expiration of study drug
- Trial completion: Natural History of Asphyxiating Thoracic Dystrophy (DTJ) (clinicaltrials.gov) - Dec 11, 2011
P=N/A, N=50, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Completed --> Terminated; Lack of patient availability and expiration of study drug Recruiting --> Completed
- | lenalidomide / Generic mfg.
Trial initiation date: LENAKAP: Lenalidomide in Kaposi Disease Associated With HIV Infection (clinicaltrials.gov) - Dec 8, 2011
P2, N=35, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Recruiting --> Completed Initiation date: Jul 2011 --> Oct 2011